X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (696) 696
immunotherapy (634) 634
oncology (612) 612
anti-pd-1 (576) 576
humans (557) 557
nivolumab (408) 408
melanoma (391) 391
cancer (387) 387
ipilimumab (342) 342
anti-pd-1 antibody (323) 323
safety (290) 290
pembrolizumab (269) 269
immunology (239) 239
female (223) 223
metastatic melanoma (200) 200
care and treatment (197) 197
male (190) 190
pd-1 (190) 190
chemotherapy (188) 188
metastasis (188) 188
tumors (181) 181
middle aged (173) 173
aged (166) 166
programmed cell death 1 receptor - antagonists & inhibitors (166) 166
blockade (165) 165
open-label (156) 156
patients (156) 156
therapy (155) 155
apoptosis (148) 148
animals (147) 147
antibodies, monoclonal - therapeutic use (144) 144
cancer therapies (140) 140
survival (140) 140
lymphocytes (134) 134
melanoma - drug therapy (134) 134
antineoplastic agents - therapeutic use (131) 131
immune checkpoint (125) 125
adult (123) 123
anti-pd-1 therapy (121) 121
clinical trials (121) 121
research (118) 118
advanced melanoma (117) 117
pd-1 blockade (115) 115
analysis (114) 114
lung cancer (113) 113
pd-l1 (113) 113
programmed cell death 1 receptor - immunology (111) 111
immunotherapy - methods (110) 110
treatment outcome (109) 109
antibody (106) 106
cell lung-cancer (106) 106
expression (106) 106
antibodies, monoclonal - adverse effects (102) 102
pd-1 protein (97) 97
t-cells (97) 97
t cells (95) 95
immune checkpoint inhibitors (94) 94
medicine, research & experimental (91) 91
antibodies (90) 90
review (90) 90
antineoplastic agents - adverse effects (88) 88
cell death (88) 88
aged, 80 and over (87) 87
health aspects (85) 85
anti-ctla-4 (84) 84
drug therapy (84) 84
docetaxel (82) 82
antigens (78) 78
antibodies, monoclonal, humanized - therapeutic use (76) 76
b7-h1 antigen - antagonists & inhibitors (76) 76
ligands (76) 76
melanoma - pathology (75) 75
article (74) 74
adverse events (73) 73
medical prognosis (73) 73
lymphocytes t (72) 72
neoplasms - immunology (72) 72
pharmacology & pharmacy (72) 72
prognosis (72) 72
cytotoxicity (70) 70
lung cancer, non-small cell (67) 67
usage (67) 67
skin neoplasms - drug therapy (66) 66
antibodies, monoclonal, humanized - adverse effects (65) 65
immune response (65) 65
neoplasms - drug therapy (65) 65
medical research (64) 64
mice (64) 64
biomarkers (63) 63
cell biology (62) 62
metastases (62) 62
toxicity (62) 62
ctla-4 (61) 61
medicine & public health (61) 61
immune system (60) 60
lung neoplasms - drug therapy (60) 60
monoclonal antibodies (59) 59
pd-l1 protein (59) 59
ctla-4 blockade (58) 58
melanoma - immunology (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1111) 1111
French (18) 18
German (13) 13
Korean (3) 3
Polish (1) 1
Russian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2017, Volume 35, Issue 7, pp. 709 - 717
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 210 - 225
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1403 - 1414
Journal Article
Clinical journal of oncology nursing, ISSN 1092-1095, 08/2017, Volume 21, Issue 4, pp. 30 - 41
BACKGROUND: Ipilimumab (Yervoy (R)) therapy improves outcomes in patients with resected stage III melanoma, and ipilimumab alone or combined with nivolumab... 
melanoma | nivolumab | CTLA4 inhibitor | immune-related adverse events | ipilimumab | DIAGNOSIS | IMMUNE CHECKPOINT INHIBITORS | MANAGEMENT | STAGE-III MELANOMA | NURSING | CANCER-IMMUNOTHERAPY | ANTI-PD-1 ANTIBODIES | TOXICITIES | PEMBROLIZUMAB | ANTI-CTLA-4 | ONCOLOGY | BLOCKADE | Complications and side effects | Oncologic nursing | Ipilimumab | Melanoma | Dosage and administration | Drug therapy | Methods | Nursing
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 190 - 209
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 12, pp. 3168 - 3180
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2288 - 2294
Journal Article
OncoImmunology, ISSN 2162-4011, 09/2016, Volume 5, Issue 9, pp. e1214788 - e1214788
The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and... 
radiotherapy | melanoma | Anti-pd-1 antibody | immunotherapy | RANDOMIZED-TRIAL | WHOLE-BRAIN RADIOTHERAPY | IMMUNOLOGY | TUMORS | CELL LUNG-CANCER | UNTREATED MELANOMA | STEREOTACTIC RADIOSURGERY | ONCOLOGY | RADIATION NECROSIS | NIVOLUMAB | BLOCKADE | IPILIMUMAB
Journal Article
Journal Article